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OBJECTIVE—The causal nature of associations between circu-
lating triglycerides, insulin resistance, and type 2 diabetes is
unclear. We aimed to use Mendelian randomization to test the
hypothesis that raised circulating triglyceride levels causally
inﬂuence the risk of type 2 diabetes and raise normal fasting
glucose levels and hepatic insulin resistance.
RESEARCH DESIGN AND METHODS—We tested 10 com-
mon genetic variants robustly associated with circulating tri-
glyceride levels against the type 2 diabetes status in 5,637 case
and 6,860 control subjects and four continuous outcomes
(reﬂecting glycemia and hepatic insulin resistance) in 8,271
nondiabetic individuals from four studies.
RESULTS—Individuals carrying greater numbers of triglyceride-
raising alleles had increased circulating triglyceride levels (SD
0.59 [95% CI 0.52–0.65] difference between the 20% of individuals
with the most alleles and the 20% with the fewest alleles). There was
no evidence that the carriers of greater numbers of triglyceride-
raising alleles were at increased risk of type 2 diabetes (per
weighted allele odds ratio [OR] 0.99 [95% CI 0.97–1.01]; P =0 . 2 6 ) .
In nondiabetic individuals, there was no evidence that carriers of
greater numbers of triglyceride-raising alleles had increased fasting
insulin levels (SD 0.00 per weighted allele [95% CI 20.01 to 0.02];
P = 0.72) or increased fasting glucose levels (0.00 [20.01 to 0.01];
P = 0.88). Instrumental variable analyses conﬁrmed that geneti-
cally raised circulating triglyceride levels were not associated
with increased diabetes risk, fasting glucose, or fasting insulin
and, for diabetes, showed a trend toward a protective association
(OR per 1-SD increase in log10 triglycerides: 0.61 [95% CI 0.45–
0.83]; P = 0.002).
CONCLUSIONS—Genetically raised circulating triglyceride lev-
els do not increase the risk of type 2 diabetes or raise fasting
glucose or fasting insulin levels in nondiabetic individuals. One
explanation for our results is that raised circulating triglycerides
are predominantly secondary to the diabetes disease process
rather than causal. Diabetes 60:1008–1018, 2011
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aised circulating triglyceride levels are strongly
correlated with insulin resistance, raised glucose
levels, and type 2 diabetes (1–8), but the causal
nature of these associations is unclear because
of the complex interactions between fat, muscle, and liver
insulin resistance, dyslipidemia, and insulin secretion by
b-cells.
Several lines of evidence suggest that raised triglyceride
levels could causally inﬂuence the risk of type 2 diabetes,
high glucose levels, and insulin resistance. Accumulation
of triglycerides in tissues other than adipose has been
proposed to result in lipotoxicity, a process that may in-
crease the risk of type 2 diabetes. For example, excess
triglycerides in the liver causes fatty liver disease and is
thought to impair hepatic insulin signaling, resulting in
insulin resistance (reviewed in [9]), whereas exposure of
the b-cell to free fatty acids (FFAs) is thought to impair
insulin secretion (10–13).
Epidemiological data support a possible etiological role
for raised triglyceride levels in insulin resistance and type
2 diabetes. Raised serum triglycerides predict incident
type 2 diabetes independently of BMI (1–4,6,14–16), al-
though prospective evidence does not rule out the possi-
bility that early disease processes can inﬂuence such
associations. Data from some trials show that individuals
receiving lipid-lowering therapies are less likely to develop
type 2 diabetes (14,17–19). These ﬁndings have led to the
proposal that therapies that lower circulating triglycerides
could be used to improve insulin sensitivity and reduce the
risk of type 2 diabetes (20–22).
One useful method to help dissect the causal nature of
the correlations between metabolic traits is Mendelian
randomization (23). This approach uses the principle that
the random assortment of genotypes in meiosis is in-
dependent of nongenetic factors, including environmental
risk factors, confounding factors, or disease processes.
There are good proof-of-principle examples of Mendelian
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ORIGINAL ARTICLErandomization. These include the association between
FTO genotypes, which are robustly associated with total
fat mass, and type 2 diabetes and blood pressure, which
conﬁrmed the causal associations between adiposity and
these outcomes (24,25), and the association between LDL
cholesterol–associated variants and heart disease (26).
In this study, we extend the Mendelian randomization
approach to test the hypothesis that raised circulating
triglyceride levels have an etiological role in type 2 di-
abetes, raised fasting glucose levels, and fasting-based
measures of insulin resistance.
RESEARCH DESIGN AND METHODS
Type 2 diabetes case-control study. We studied 12,497 individuals (5,637
type 2 diabetic patients and 6,860 control subjects) from the Genetics of Di-
abetes Audit and Research in TaysideScotland(Go-DARTS)study(27), across-
sectional study that includes measures of circulating lipids, often with
repeated measurements in the same individual (Table 1). Patients were ex-
cluded if their age at diagnosis was ,35 or .70 years or if they needed insulin
treatment within 1 year of diagnosis. For 2.1% of patients, age at diagnosis was
not known, in which case those aged ,45 years at the time of study were
excluded. Control status was deﬁned if individuals were between 35 and
80 years of age with an A1C ,6.4% and/or fasting glucose ,7 mmol/L. Anal-
yses of associations involving triglyceride levels were limited to the 9,693
individuals (3,976 patients and 5,717 control subjects) that had triglyceride
levels measured prior to taking any lipid-lowering medication. Of these indi-
viduals, 46.88% (74.72% of patients and 27.51% of control subjects) had more
than one measure of triglycerides, in which case we used mean values.
Fasting-based measures of insulin resistance and glucose levels. For the
study of continuous traits, we examined nondiabetic individuals from four
studies. These studies were the Exeter Family Study of Childhood Health
(EFSOCH) (28), the Go-DARTS study, the Fenland Study (29 Supplementary
Information), and the British Women’s Heart and Health Study (BWHHS) (30)
(Table 1). The EFSOCH study consisted of parents of babies born between
2000 and 2004 from Exeter, U.K. For EFSOCH mothers, we used fasting
measures taken postpregnancy. The Go-DARTS subjects are a subset of those
studied as control subjects in the type 2 diabetes study described above, who
had fasting glucose, insulin, and nonfasting lipid measures available (fasting
lipid measures were not taken). The Fenland Study is a population-based
study in the East Cambridgeshire and Fenland areas of the U.K. The BWHHS
is a prospective cohort study of women aged 60–79 years recruited from
23 towns across Britain from 1999 to 2000.
We only included individuals with fasting glucose values ,7.0 mmol/L. None
of the individuals in the EFSOCH study, 26 (,2%) in the Fenland Study, and
5% in the BWHHS were on lipid-lowering medications. We did not use tri-
glyceride measures from individuals on lipid-lowering medications in the Go-
DARTS study. Details of fasting glucose and fasting insulin measurement
methods are given in Supplementary Table 1. We calculated additional fasting-
based measures of insulin resistance and b-cell function using the homeostasis
model assessment of b-cell function (HOMA-B) and HOMA of insulin re-
sistance (HOMA-IR) using the HOMA calculator (available at http://www.dtu.
ox.ac.uk).
Selection of single nucleotide polymorphisms, genotyping, and quality
control. We initially selected 12 independent single nucleotide polymorphisms
(SNPs) that are associated with circulating triglyceride levels at genome-wide
levels of signiﬁcance (P , 5 3 10
28) (31–35). We excluded two of these SNPs
from our analyses (FADS1-rs174547 and GCKR-rs1260326) because they are
strongly associated with several other quantitative traits relevant to diabetes
(29,36,37).
We genotyped 10 selected SNPs in the four studies using either a modiﬁed
Taqman assay, a KASPAR assay (http://www.kbioscience.co.uk), directly or
imputed genotypes from the Affymetrix GeneChip Human Mapping 500 K ar-
ray, or the Illumina Human CVD array (Supplementary Methods). The geno-
typing success rate for each SNP was .92% in all studies, and the concordance
rate between duplicates (at least 7% of samples) was at least 97%. All 10 var-
iants were in Hardy-Weinberg equilibrium in each of the four studies (P .
0.05).
Statistical analyses. We used two approaches to assess the relationship
between circulating triglyceride levels and diabetes-related outcomes: the
triangulation approach outlined in Fig. 1 and an instrumental variable ap-
proach (38). All statistical analyses were performed using Stata/SE version
10.1 for Windows (StataCorp, Brownsville, TX). Meta-analyses were per-
formed using the inverse-variance weighted ﬁxed-effects estimator imple-
mented in the Stata command, “metan.”
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In each study, triglyceride levels (mmol/L) were log10 transformed before
analysis. For the type 2 diabetes study, we generated age- and sex-corrected
z scores of log10-transformed triglycerides, using all case and control subjects.
To estimate the SNP versus triglyceride associations, we assumed a preva-
lence rate of 5% for type 2 diabetes in the U.K., and to be more representative
of this general population we gave a weight of 95% to control subjects and 5%
to case subjects. For continuous traits, we generated within-study z scores of
log10-transformed triglycerides using the means and SD of the samples, where
age, sex, triglyceride levels, and genotypes from at least eight of 10 SNPs were
available.
Using both individual SNPs and a weighted allele score, we tested associ-
ations between genotypes and triglyceride levels. To create the weighted allele
score, we used individuals with genotypes available from at least eight of 10
SNPs and accounted for the varying effect sizes of each SNP using equation 1,
where w is the b-coefﬁcient from the individual regressions of the SNP ge-
notype against triglycerides.
Weighted score ¼ w1 3SNP1 þ w2 3SNP2 þ :::::::::::::::::::::: þ wn 3SNPn
ð1Þ
We rescaled the weighted score to reﬂect the number of available SNPs
(ranging from 8 to 10) using equation 2, as described in Lin et al. (39). For all
further tests, we used this allele score.
Allele score ¼
Weighted score3Number of SNPs available
Sum weights of the available SNPs
ð2Þ
We used this allele score as the independent variable and the log10-triglyceride
z score as the dependent variable, and for the study of continuous traits we
also used age and sex as covariates in linear regression analyses. In addition,
we stratiﬁed individuals in each study into quintiles consisting of the 20% of
individuals with increasing numbers of (weighted) triglyceride-raising alleles.
Observed association between triglycerides and outcomes. Using 3,976
case and 5,717 control subjects from the Go-DARTS study, we estimated the
odds ratio (OR) for type 2 diabetes per 1-SD increase in log10-triglyceride
z score in a logistic regression analysis. For the four nondiabetes studies, we
tested four continuous-outcome variables: fasting glucose, fasting insulin,
HOMA-B, and HOMA-IR. We log10 transformed the outcome variables that
were skewed and created z score within each study. We used the log10-
triglyceride z score as the independent variable and each outcome z score as
the dependent variable, with age and sex as covariates in linear regression
analyses prior to meta-analysis.
Observed association between triglyceride SNPs and outcomes. To test
the association between triglyceride SNPs and type 2 diabetes, we used in-
dividual SNPs or the allele score as the independent variable and type 2 di-
abetes status as the dependent variable in logistic regression analyses, with age
and sex as covariates. To test the association between triglyceride SNPs and
continuous outcomes, we performed the same analyses but in linear regression
models prior to meta-analysis.
Calculation of the approximate expected effect size of the association
between triglyceride SNPs and outcomes. If raised triglyceride levels are
etiologically associated with the outcomes, then under certain assumptions we
would expect the point estimate of the expected outcome (a per-allele OR for
type 2 diabetes, or SD effect size for continuous traits; Fig. 1d) to be a function
of 1) the SNP-triglyceride association and 2) the triglyceride-outcome asso-
ciation (i.e., d = SD effect size of a 3 SD effect size/OR of b in Fig. 1). SEs for
the expected effect sizes were calculated using the Taylor series expansion of
the ratio of two means (40).
Instrumental variable analysis. To estimate the causal effect of triglycerides
on outcomes, we performed instrumental variable analyses (Supplementary
Methods and Supplementary Fig. 2). An instrumental variable analysis relates
the variation in the potentially causal risk factor of interest (here, circulating
triglyceride levels) that is inﬂuenced by the “instrument” (here, triglyceride
genotypes) to the outcome (here, type 2 diabetes, fasting insulin, or fasting
glucose levels). This method makes the assumption that the instrumental
variable is not associated with measured or unmeasured confounders (likely
to be true for genetic variants [38]) and is only related to the outcome via its
effect on the risk factor. This produces an estimate of the causal effect in a similar
way as an intention-to-treat analysis in a randomized controlled trial (38).
Instrumental variable analysis for type 2 diabetes case-control
status. We limited this analysis to the 8,335 individuals (3,090 case and
5,245 control subjects) whohad triglyceride levels measuredprior totakingany
lipid-lowering medication and genotypes from at least eight of 10 triglyceride
SNPs. Instrumental variable analysis was performed using a logistic control
function estimator (41). The analysis was performed in two stages. In the ﬁrst
stage, we assessed the observational association between allele score and
triglyceride z score, as described in Fig. 1a. We saved the predicted values and
residuals from this regression model. In the second stage, we used the pre-
dicted values from stage 1 as the independent variable (reﬂecting an un-
confounded estimate of triglyceride levels attributed to these genotypes) and
FIG. 1. Triangulation approach used to estimate the expected association for the SNP vs. type 2 diabetes or continuous trait (d) given the SNP
versus triglyceride association (a) and the triglyceride versus type 2 diabetes or continuous trait associations (b).
MENDELIAN RANDOMIZATION IN TYPE 2 DIABETES
1010 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgdiabetes status as the dependent variable in a logistic regression analysis. The
residuals from stage 1 were included as a covariate, representing residual
variation in triglyceride levels that is not attributed to these genotypes (41).
We then used a Wald test to assess the evidence of a difference between the
predicted-values coefﬁcient (instrumental variable estimate of the causal ef-
fect of triglyceride levels on type 2 diabetes) and the residuals coefﬁcient as
test of endogeneity.
Instrumental variable analyses for fasting insulin, fasting glucose,
HOMA-B, and HOMA-IR. We performed the instrumental variable estimation
for each outcome in each study using the two-stage least-squares estimator,
implemented in the Stata command “ivreg2.” We tested for a difference be-
tween the instrumental variable and observational estimates using the Durbin-
Wu-Hausman test of endogeneity. We meta-analyzed the instrumental variable
estimates for each outcome from the individual studies.
Effects of triglyceride SNPs on HDL, LDL, and total cholesterol and
effects when including GCKR and FADS1 SNPs. We performed additional
analyses, including tests on other lipid parameters to assess whether the results
are predominantly driven by the variants’ effects on triglycerides. This was
assessed by tests, including only the four SNPs with the weakest effects on
HDL cholesterol relative to their effects on triglycerides (the SNPs in or near
MLXIPL, ANGPTL3, NCAN,a n dTRIB1) in the allele score. We also assessed
the effects when including the GCKR and FADS1 SNPs in the allele score and
the effects when adjusting for BMI in addition to age and sex (Supplementary
Methods).
RESULTS
Observed association between triglyceride SNPs and
triglycerides. Associations between individual SNPs and
triglycerides, meta-analyzed across each of the four stud-
ies with nondiabetic individuals, and separately for the
type 2 diabetes study, are shown in Table 2. The majority
was highly signiﬁcantly associated with circulating tri-
glyceride levels, and all effects were consistent with those
reported in genome-wide association studies. Individuals
carrying greater numbers of (weighted) triglyceride-raising
alleles had increased circulating triglyceride levels (Table 2,
Fig. 2A, and Supplementary Fig. 1). For example, the group
of individuals in the highest quintile of the weighted allele
score had triglyceride levels that were 0.59 SDs (95% CI
0.52–0.65) higher than those in the lowest quintile. There
was some evidence (I
2 =7 8 . 6 % ,P = 0.003) for heterogeneity
between studies for the allele score–triglyceride association
(Supplementary Fig. 1), but a random-effects meta-analysis
resulted in a similar point estimate (data not shown).
Observed association between triglycerides and out-
comes. A 1-SD increase in log10-triglyceride levels was
associated with an OR of 2.68 (95% CI 2.54–2.82) for type 2
diabetes in the Go-DARTS study. Triglyceride levels were
associated with each of the four continuous outcomes
across the four nondiabetes studies. A 1-SD increase in
triglyceride levels was associated with 0.12 SDs (95% CI
0.1–0.15), 0.36 SDs (0.33–0.38), 0.41 SDs (0.38–0.43), and
0.40 SDs (0.38–0.42) higher fasting glucose, HOMA-B,
fasting insulin, and HOMA-IR, respectively (Table 3 and
Fig. 3A). There was some evidence for heterogeneity be-
tween the nondiabetic studies for the associations in-
volving fasting insulin (I
2 = 74.6%, P = 0.008), fasting
glucose (I
2 =6 9 . 5 % ,P = 0.02), and HOMA-IR (I
2 =7 5 . 7 % ,P =
0.006). Random-effects meta-analyses resulted in similar
point estimates (data not shown).
Observed association between triglyceride SNPs and
type 2 diabetes. The details of the individual associations
between triglyceride SNPs and type 2 diabetes are given
in Table 4. None of the SNPs were associated with type 2
diabetes (P . 0.01). There was no evidence that individuals
TABLE 2
The association of individual SNPs and combinations of SNPs with circulating triglyceride levels from a meta-analysis of four studies
of nondiabetic individuals and the Go-DARTS type 2 diabetes case-control study
SNP/weighted allele score Nearest gene*
SNP(s) vs. triglycerides
(continuous-traits meta-analysis)†
SNP(s) vs. triglycerides (type 2
diabetes case-control analysis)
Triglyceride z score
per allele (95% CI) P
Heterogeneity
P (I
2%)
Triglyceride
z score per
allele (95% CI) P
rs2954029 TRIB1 0.10 (0.07–0.13)‡ 6 3 10
212 0.19 (37.5) 0.08 (0.05–0.12)‡ 4 3 10
27
rs714052 MLXIPL 0.15 (0.11–0.20)‡ 2 3 10
211 0.81 (0.0) 0.13 (0.08–0.18)‡ 1 3 10
27
rs7557067 APOB 0.05 (0.02–0.09)‡ 0.002 0.62 (0.0) 0.07 (0.03–0.10)‡ 0.001
rs17216525 NCAN, CLIP2, PBX4 0.11 (0.05–0.16)‡ 8 3 10
25 0.42 (0.0) 0.04 (20.02 to 0.10)‡ 0.16
rs10889353 ANGPTL3 0.06 (0.03–0.09)‡ 2 3 10
24 0.36 (6.8) 0.05 (0.01–0.08)‡ 0.008
rs7679 PLTP 0.05 (0.02–0.09)‡ 0.005 0.41 (0.0) 0.06 (0.01–0.10)‡ 0.008
rs7819412 XKR6-AMAC1L2 0.03 (0.00–0.06)‡ 0.043 0.82 (0.0) 0.01 (20.02 to 0.04)‡ 0.54
rs328 LPL 0.21 (0.16–0.26)‡ 4 3 10
217 0.38 (2.1) 0.21 (0.16–0.27)‡ 2 3 10
215
rs3135506 APOA5 0.24 (0.18–0.30)‡ 1 3 10
214 0.33 (13.0) 0.17 (0.10–0.25)‡ 5 3 10
26
rs662799 APOA5 0.25 (0.18–0.31)‡ 1 3 10
214 0.60 (0.0) 0.17 (0.10–0.27)‡ 1 3 10
26
Allele score 0.12 (0.10–0.13)§ 9 3 10
276 0.003 (78.6) 0.09 (0.08–0.11)§ 2 3 10
241
Q2 vs. Q1 0.22 (0.15–0.28)|| 2 3 10
211 0.93 (0.0) 0.17 (0.10–0.24)|| 4 3 10
26
Q3 vs. Q1 0.32 (0.26–0.39)|| 3 3 10
223 0.78 (0.0) 0.29 (0.21–0.36)|| 5 3 10
215
Q4 vs. Q1 0.38 (0.32–0.45)|| 3 3 10
232 0.85 (0.0) 0.33 (0.26–0.40)|| 5 3 10
219
Q5 vs. Q1 0.59 (0.52–0.65)|| 2 3 10
272 0.16 (41.3) 0.43 (0.36–0.50)|| 4 3 10
231
Q = quintile of weighted allele score. The sample size in the allele score vs. triglyceride association was 8,084 and 8,335 in meta-analyses of the
four continuous-outcome studies and Go-DARTS type 2 diabetic case and control subjects, respectively. For quintiles of allele score versus
triglyceride analyses, the sample sizes ranged from 3,222 to 3,240 in continuous-traits meta-analyses and 3,315 to 3,372 in Go-DARTS type 2
diabetic case and control subjects. *Nearest gene information reported as in Kathiresan et al. (31), except for rs328, which is from Kathiresan
et al. (34) and for rs3135506 and rs662799, which are from Pennacchio et al. (32). †Results from the continuous-traits meta-analysis and type 2
diabetes case-control analysis are not independent. A subset of control subjects from the type 2 diabetes case-control study are used in the
continuous-traits study (those with fasting glucose ,7.0 mmol/L and fasting insulin, triglycerides, and 8 of the 10 SNPs available). The effect
sizes reported are ‡change in triglyceride z score per triglyceride-raising allele for individual SNPs, §change in triglyceride z score per unit
increase in weighted allele score, or ||difference in triglyceride z score between the relevant quintiles of the weighted allele score.
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alleles were at increased risk for type 2 diabetes (Table 4
and Fig. 2B).
Observed association between triglyceride SNPs and
fasting insulin, fasting glucose, HOMA-B, and HOMA-
IR. Associations between individual SNPs and each
continuous outcome, meta-analyzed across the four non-
diabetic studies, are given in Table 5 and Supplementary
Table 2. None of the SNPs were associated with any of the
four outcomes except for rs7819412 (XKR6-AMAC1L2
locus), where there was some evidence for a positive as-
sociation with fasting insulin (P = 0.004) and HOMA-IR
(P = 0.004). There was no evidence that carriers of greater
numbers of (weighted) triglyceride-raising alleles were at
risk for increased fasting glucose or fasting insulin levels
(Table 5, Fig. 3B, and Supplementary Table 2). There was
no heterogeneity between studies except for the allele
score–glucose association (I
2 = 80.9%, P = 0.001) and
removing the one study inﬂuencing this heterogeneity, Go-
DARTS, resulted in a nominal association between allele
score and raised fasting glucose (P = 0.03).
Expected effect size of the association between
triglyceride SNPs and type 2 diabetes. Estimates of
the expected ORs and 95% CIs for the allele score–type 2
diabetes association are shown in Table 4. For the allele
score and each quintile comparison, the 95% CIs of the
observed ORs excluded the expected point estimate
ORs estimated from the function of the SNP–triglyceride
and triglyceride–type 2 diabetes correlations and vice
versa.
Expected effect size of the association between tri-
glyceride SNPs and fasting insulin, fasting glucose,
HOMA-B, and HOMA-IR. Estimates of the expected ef-
fect sizes and the 95% CIs for the allele score–continuous
outcome associations are given in Table 5 and Supplementary
Table 2. For the allele score and each quintile comparison,
FIG. 2. The combined impact of the 10 triglyceride-associated SNPs on circulating triglyceride levels in the Go-DARTS study type 2 diabetic case
and control subjects, with triangles representing the mean triglyceride z score within each triglyceride-increasing allele group (A); and observed
(circles) and expected (triangles) type 2 diabetes ORs when comparing each allele group to a reference group of those with six or fewer
triglyceride-raising alleles, with 95% CIs given for the observed data points (B). Participants were grouped by total number of triglyceride-raising
alleles at all 10 SNPs, and the bars represent the number of individuals in each group.
MENDELIAN RANDOMIZATION IN TYPE 2 DIABETES
1012 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgthe 95% CIs of the observed effect sizes excluded the ap-
proximate expected effect sizes estimated from the function
of the SNP–triglyceride and triglyceride–outcome correla-
tions and vice versa.
Instrumental variable estimate for type 2 diabetes.
Instrumental variable estimation provided strong evidence
that raised circulating triglyceride levels do not causally re-
sult in an increased risk of type 2 diabetes. Instead, there
FIG. 3. Meta-analysis of continuous traits. Triglyceride–outcome associations (A), weighted triglyceride allele score–outcome associations (B),
and instrumental variable analyses of triglyceride–outcome associations (C), all corrected for age and sex across the four studies of nondiabetic
individuals.
TABLE 3
Meta-analysis results of observed and instrumental variable analyses of triglyceride–continuous outcome associations
Trait
Observed change in outcome z score per 1-SD increase
in log10-triglycerides
Instrumental variable estimate of change
in outcome z score per 1-SD increase in
log10-triglycerides
Effect size (95% CI) P Heterogeneity P (I
2%) Effect size (95% CI) P Heterogeneity P (I
2%)
Fasting insulin 0.41 (0.38–0.43) ,0.001 0.008 (74.6) 0.04 (20.08 to 0.16) 0.49 0.12 (48.2)
Fasting glucose 0.12 (0.10–0.15) ,0.001 0.02 (69.5) 0.01 (20.10 to 0.12) 0.90 0.002 (79.4)
HOMA-IR 0.40 (0.38–0.42) ,0.001 0.006 (75.7) 0.04 (20.08 to 0.16) 0.51 0.13 (47.3)
HOMA-B 0.36 (0.33–0.38) ,0.001 0.11 (49.7) 0.01 (20.11 to 0.13) 0.83 0.27 (23.7)
The sample sizes for the triglyceride vs. outcome associations ranged from 6,705 to 8,227 and from 6,519 to 8,040 for instrumental variable
meta-analyses.
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[genetically inﬂuenced] circulating triglycerides was associ-
ated with an OR for type 2 diabetes of 0.61 [95% CI 0.45–0.83];
P = 0.002). There was strong evidence that the instru-
mental variable OR (0.61 [0.45–0.83]) and standard OR
(2.68 [2.53–2.84]) estimates were different from each other
(P =63 10
221).
Instrumental variable estimates for fasting insulin,
fasting glucose, HOMA-B, and HOMA-IR. Instrumental
variable estimation gave strong evidence that genetically
inﬂuenced circulating triglyceride levels do not have a
causal effect on fasting insulin, fasting glucose, HOMA-B, or
HOMA-IR (Table 3 and Fig. 3C) .A sf o u n dw i t ht h e
standard analyses described in the section “Observed
association between triglyceride SNPs and fasting in-
sulin, fasting glucose, HOMA-B, and HOMA-IR,” there
was evidence of heterogeneity in the instrumental vari-
able analysis with fasting glucose as an outcome (I
2 =
79.4%, P = 0.002), and removing the Go-DARTS study
control subjects, who caused this heterogeneity (Fig. 3C),
resulted in nominal evidence of the association of in-
creased triglycerides with increased glucose levels (P =
0.08). For all four outcomes, the instrumental variable
estimates from the meta-analyses were inconsistent with
estimates observed from standard regression analyses
(Table 3).
Effects of triglyceride SNPs on HDL, LDL, and total
cholesterol and effects when including GCKR and
FADS1 SNPs. We found very similar results in the se-
ries of sensitivity analyses with some possible exceptions.
First, using the weighted allele score containing the four
SNPs with disproportionately greater effects on triglyc-
erides relative to HDL, we observed a possible stronger
protective effect of higher triglycerides on type 2 diabetes
(instrumental variable analysis: OR per 1-SD increase in
log10-triglycerides: 0.34 [95% CI 0.19–0.59]; P = 0.0001)
(Supplementary Table 4). Second, including the GCKR and
FADS1 SNPs in the weighted allele model resulted in
a possible protective association with fasting glucose lev-
els compared with when these SNPs were not included
(Supplementary Table 5). Third, adjusting for BMI resulted
in a possible stronger protective effect of higher triglyc-
erides on type 2 diabetes (0.35 [0.20–0.64]; P =0 . 0 0 1 ) ,
compared with when not adjusting for BMI (Supplementary
Table 6).
DISCUSSION
Using a Mendelian randomization approach, our results
show strong evidence that higher circulating triglyceride
levels do not increase type 2 diabetes risk, fasting glucose,
or fasting-based measures of insulin resistance. Our results
are consistent with lifelong, raised circulating triglycerides
conferring no net harm to the liver or b-cell. Our results
suggest that alternative explanations are needed to explain
the observational associations between raised triglyceride
levels and diabetes and related traits. These explanations
could include confounding factors or reverse-direction
causal effects (i.e., type 2 diabetes and insulin resistance
causing raised triglycerides). Other human genetic studies
support the reverse-causation argument. For example,
postreceptor defects in insulin resistance caused by AKT
mutations result in increased hepatic lipogenesis and in-
creased circulating triglycerides (8), and polymorphisms
near the IRS1 gene that are robustly associated with in-
sulin resistance (42) also result in raised triglycerides (43)
(both associations at conventional levels of genome-wide
signiﬁcance, P , 5 3 10
28).
TABLE 4
The association of individual and combinations of SNPs with type 2 diabetes in the Go-DARTS type 2 diabetes case-control study
SNP Nearest genes*
Type 2 diabetes OR
per allele (95% CI) P
Expected OR† =
a 3 b (95% CI)
rs108893353 ANGPTL3 0.97 (0.91–1.03) 0.27
rs17216525 NCAN, CLIP2, PBX4 0.89 (0.80–0.99) 0.03
rs2954029 TR1B1 1.01 (0.95–1.06) 0.83
rs714052 MLXIPL 0.96 (0.89–1.05) 0.38
rs7557067 APOB 1.00 (0.93–1.07) 0.99
rs7679 PLTP 0.98 (0.91–1.06) 0.64
rs7819412 XKR6-AMAC1L2 0.97 (0.91–1.03) 0.26
rs328 LPL 1.02 (0.93–1.12) 0.69
rs3135506 APOA5 1.04 (0.92–1.18) 0.52
rs662799 APOA5 1.00 (0.88–1.12) 0.97
Allele score 0.99 (0.96–1.01) 0.26 1.10 (1.08–1.12)
Q1 vs. Q2 0.95 (0.84–1.07) 0.39 1.19 (1.09–1.30)
Q1 vs. Q3 0.89 (0.79–1.01) 0.08 1.32 (1.19–1.46)
Q1 vs. Q4 0.90 (0.80–1.02) 0.11 1.37 (1.24–1.53)
Q1 vs. Q5 0.93 (0.82–1.06) 0.27 1.52 (1.34–1.72)
Q = quintile of weighted allele score. *Nearest gene information reported as in Kathiresan et al. (31), except for rs328, which is from
Kathiresan et al. (34), and for rs3135506 and rs662799, which are from Pennacchio et al. (32). The sample sizes ranged from 10,378 to
10,574 for the individual SNP(s) vs. type 2 diabetes analyses. The number of individuals in the weighted allele score vs. type 2 diabetes
analyses is 10,676 and ranged from 4,212 to 4,318 for quintiles of the allele score vs. type 2 diabetes analyses. The total number of individuals in
the SNP(s) vs. type 2 diabetes analyses is greater than the corresponding SNP(s) vs. triglyceride analyses in Table 2 because the numbers in
the latter were also restricted by the number of individuals with pretreatment triglyceride levels measured. The results for the SNP(s) vs. type
2 diabetes analyses were similar when we restricted the analyses to individuals with pretreatment triglycerides measured. †The point estimate
of the expected OR for the allele score vs. type 2 diabetes was calculated by multiplying (in Fig. 1a) the effect size of the allele score vs. the
triglyceride association by (in Fig. 1b) the OR of the triglyceride vs. type 2 diabetes association. For example, the expected type 2 diabetes OR
for Q1 vs. Q2 was calculated by multiplying the effect size of the allele score vs. triglyceride association for the Q1 vs. Q2 comparison (0.17
SDs) by the natural log of the relevant triglyceride vs. type 2 diabetes OR (i.e., natural log of 2.9). The exponent of the answer from this
multiplication is the expected type 2 diabetes OR for Q1 vs. Q2.
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proach. The main strength is that we used genetic variants
to test a complex relationship between metabolic traits.
Because genetic variation is randomly sorted at meiosis,
associations between SNPs and metabolic traits are un-
likely to be biased, confounded, or inﬂuenced by disease
processes. Furthermore, the effects of the genetic variants
we have used are likely to reﬂect lifelong exposure to al-
tered circulating triglycerides. In contrast, it is extremely
difﬁcult to disentangle likely causal directions between
correlated human phenotypes using nongenetic approaches
(38), and this is especially true for associations between
metabolic factors such as lipid levels, diabetes, and insulin
resistance (7). The second strength of our study is the
statistical power. Because we used 10 common variants,
our weighted allele score model compared large numbers
of people with large differences in genetically inﬂuenced
circulating triglyceride levels; for example, 20% of individ-
uals carrying the most triglyceride-raising alleles had cir-
culating levels 0.59 SDs higher than the 20% carrying the
fewest. We therefore had very good power to see an effect
of triglyceride variants on related metabolic traits if such
a relationship existed (for example .80% power at P =0 . 0 5
if circulating triglycerides 0.59 SDs higher than a baseline
group resulted in a type 2 diabetes OR of 1.12). The third
strength is that we used 10 variants that are likely to in-
ﬂuence circulating triglyceride levels in a variety of ways.
Although genome-wide association studies do not identify
the causal gene involved, variants in or near LPL and
ANGPTL3 are likely to inﬂuence lipoprotein lipase func-
tion, the key enzyme located in capillary surfaces that
hydrolyses triglycerides to release fatty acids (44,45). Var-
iants in APOA5 are among those with the strongest effects
on circulating triglycerides and are likely to function
through a variety of mechanisms, including reducing liver
production of triglycerides (46,47). Variants near APOB are
most likely to affect triglyceride clearance from the liver,
and the variant at the PLTP locus is associated with altered
PLTP expression in human liver samples, suggesting that it
operates in the liver (31). Our data therefore suggest that
the lack of association between circulating triglycerides,
type 2 diabetes, and related outcomes is not dependent
on the particular mechanism that alters triglyceride levels.
A fourth strength of our study is that our results for con-
tinuous traits are consistent across four studies of different
characteristics, including mean age ranges between 33.9
and 68.8 years, mean BMIs between 25.52 and 27.24 kg/m
2,
and different ratios of male and female subjects. The ex-
ception is fasting glucose, to which the Go-DARTS study
contributes signiﬁcant heterogeneity between studies, and
the results are consistent with a small effect of triglycerides
on fasting glucose levels in the remaining three studies.
There are several limitations to our study. Most impor-
tantly, we are testing circulating, not intracellular, triglyc-
erides. We have not tested the role of triglycerides in the
liver, and fasting insulin (and HOMA-IR) is primarily
a measure of hepatic insulin resistance rather than muscle
insulin resistance. Several of the gene variants are likely to
operate in the liver by increasing the clearance of triglyc-
erides into the circulation, which could be consistent with
a lack of effect of these variants on hepatic-based mea-
sures of insulin resistance. A net effect of the triglyceride-
raising alleles on increased clearance of triglycerides from
the liver could also explain the suggestive protective as-
sociation between increased (genetically inﬂuenced) circu-
lating triglycerides and reduced risk of type 2 diabetes in the
instrumental variable analysis. However, this association
was not reﬂected by a protective association between
triglyceride-raising alleles and hepatic measures of insulin
resistance and could be attributed to chance. It will be im-
portant to test the association between triglyceride variants
and oral glucose tolerance test–based or muscle-based
measures of insulin resistance, such as those based on
hyperinsulinemic-euglycemic clamps. Therefore, our results
do not necessarily provide evidence against the lipotoxicity
hypothesis, which states that raised triglyceride levels
contribute to whole-body insulin resistance. In contrast,
our results provide stronger evidence against the lipo-
toxicity hypothesis, in that raised circulating triglyceride
levels contribute to altered b-cell function and type 2 di-
abetes. A second limitation is that we have not tested the
effects of raised circulating triglyceride levels alone but
rather a mixture of raised circulating triglycerides and, to
a lesser extent, raised LDL and total cholesterol and lower
HDL cholesterol. However, an analysis using just the four
variants with disproportionate effects on circulating tri-
glyceride levels relative to HDL cholesterol provided similar
results. With the identiﬁcation of an increasing number of
genetic variants related to lipid fractions, it will be possible
to produce multiple allele score instruments, which would
allow a demonstration of a lack of pleiotropy in generating
the observed ﬁndings. Finally, the 10 SNPs used only ac-
count for 3–5% of the phenotypic variation in circulating
triglyceride levels. We have therefore not tested the full
spectrum of genetically inﬂuenced triglyceride levels.
Further Mendelian randomization studies will be needed
to test the role of circulating FFAs, which may be more
critical to reduced b-cell function than triglycerides (48).
We excluded from our main analysis the common variant
near the FADS1 gene because this variant is most strongly
associated with polyunsaturated fatty acids (49). The FADS1
variant is also associated with fasting-based measures of
insulin secretion, such as fasting glucose and HOMA-B, and
to a lesser extent type 2 diabetes (29), suggesting that FFAs
could have a causal role in diabetes. Additional genetic
studies are needed to assess the role of FFAs and different
types of FFAs in insulin resistance and secretion.
In conclusion, we have performed a powerful Mendelian
randomization analysis of circulating triglyceride levels.
Our data provide evidence that genetically inﬂuenced raised
circulating triglyceride levels do not increase the risk of
type 2 diabetes and related metabolic traits.
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